Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2022-08-08 |
2022-06 |
-0.74 |
N/A |
N/A |
N/A |
2022-05-10 |
2022-03 |
-0.64 |
N/A |
N/A |
N/A |
2022-03-01 |
2021-12 |
0 |
N/A |
N/A |
N/A |
2021-10-29 |
2021-09 |
-0.73 |
N/A |
N/A |
N/A |
2021-08-09 |
2021-06 |
-0.7 |
N/A |
N/A |
N/A |
2021-05-10 |
2021-03 |
-0.63 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2022-05-11 |
Credit Suisse |
Upgrade |
|
Underperform |
2022-03-09 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-01-28 |
Canaccord Genuity |
Downgrade |
Buy |
Hold |
2022-01-27 |
JMP Securities |
Downgrade |
Market Outperform |
Market Perform |
2021-10-27 |
B of A Securities |
Downgrade |
Neutral |
Underperform |
2021-10-27 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2022-03-02 |
DETKE MICHAEL J |
Officer |
140.00K |
Stock Award(Grant) |
2022-05-18 |
HANNAH BRENDAN |
Officer |
16.22K |
Stock Award(Grant) |
2022-03-02 |
HOLSINGER LESLIE |
Officer |
159.00K |
Stock Award(Grant) |
2022-05-18 |
LAMOND DAVID A. |
Director |
0.00 |
Stock Award(Grant) |
2022-05-18 |
LOW PHILIP S |
Director |
0.00 |
Stock Award(Grant) |
2022-03-02 |
LOWE CHRISTOPHER P |
Chief Executive Officer |
265.00K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-03-30 |
EPIQ Capital Group, LLC |
4.08M |
7.95M |
13.53% |
2022-03-30 |
Capital World Investors |
2.49M |
4.86M |
8.27% |
2022-03-30 |
Blackrock Inc. |
1.40M |
2.74M |
4.66% |
2022-03-30 |
Vanguard Group, Inc. (The) |
1.13M |
2.20M |
3.74% |
2022-03-30 |
Morgan Stanley |
809.35K |
1.58M |
2.68% |
2022-03-30 |
JP Morgan Chase & Company |
590.42K |
1.15M |
1.96% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-03-30 |
Growth Fund Of America Inc |
1.40M |
2.73M |
4.64% |
2022-03-30 |
Smallcap World Fund |
1.08M |
2.11M |
3.59% |
2022-03-30 |
Vanguard Total Stock Market Index Fund |
522.60K |
1.02M |
1.73% |
2022-05-30 |
iShares Russell 2000 ETF |
443.60K |
865.02K |
1.47% |
2022-04-29 |
Permanent Portfolio Fund-Permanent Portfolio |
300.00K |
585.00K |
0.99% |
2022-04-29 |
Federated Hermes MDT Mid Cap Growth Fund |
241.05K |
470.05K |
0.80% |